Antiangiogenesis to treat cancer and intraocular neovascular disorders

Identification and characterization of several important regulators of angiogenesis, and FDA approval of the first anti-angiogenic drugs, has opened a new era in the therapy of cancer and neovascular age-related macular degeneration. This brief review focuses on the progress in targeting one of the major regulators of angiogenesis, VEGF-A, and also discusses potential cellular and molecular mechanisms underlying resistance to antiangiogenic treatments.